GlaxoSmithKline (GSK) is likely to attract investor attention today after announcing its Q2 FY24-25 results. The stock closed at ₹2,629.65, down 0.57% on October 29, 2024, despite solid growth in key financial metrics.
Key highlights from GSK’s Q2 performance:
- Revenue: GSK reported revenue of ₹1,011 crore, a 5% increase from ₹957 crore in Q2 FY23, reflecting steady demand for its products.
- Gross Profit: Gross profit rose by 12% year-over-year, reaching ₹305 crore compared to ₹271 crore in the same period last year, showing an improvement in margins.
- Net Profit: Net profit grew by 16%, coming in at ₹253 crore, up from ₹218 crore in Q2 FY23, highlighting a strong earnings performance.
These results underscore GSK’s steady revenue growth and profitability gains, with increases in both gross and net profit margins. Investors may keep a close eye on the stock today, as the company’s consistent performance reinforces confidence in its growth trajectory.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should perform due diligence before making investment decisions.
